结直肠黏膜内癌与高级别上皮内瘤变及T1期结直肠癌患者的临床管理比较
这项多中心队列研究纳入2010至2019年加拿大3家医院诊断的753例结直肠高级别上皮内瘤变(HGD)、黏膜内癌(IMC)或T1期结直肠癌(CRC)患者,比较完全内镜下切除后的手术比例及异时性进展风险。IMC患者完全内镜切除后接受手术的比例显著高于HGD患者(10.5% vs 0%,P < .001),但两组同步进展性肿瘤比例及异时性进展风险无显著差异,IMC淋巴结阳性率为0%(0/363)。作者认为完全内镜切除应被视为IMC的 definitive 治疗,不应常规追加手术。
要点
- IMC完全内镜切除后手术比例高于HGD(10.5% vs 0%,P < .001)。
- IMC与HGD、T1 CRC的同步进展性肿瘤比例无显著差异(P = .908)。
- IMC与HGD的异时性进展风险相似(aHR 0.82,95%CI 0.43-1.59)。
核心结论
- IMC患者完全内镜切除后接受手术的比例高于HGD患者,但本研究未观察到IMC患者同步或异时性进展性肿瘤风险增加。
- 作者认为,除非患者特别关注IMC淋巴结转移的小风险(0%-2%),完全内镜切除应被视为IMC的 definitive 治疗,不应追加手术。
研究设计与样本
- 多中心队列研究,通过病理数据库识别2010至2019年间在加拿大某区域中心3家医院诊断的HGD、IMC或T1 CRC息肉患者。
- 共识别753例首次病理诊断为IMC或HGD的患者,其中601例接受完全内镜切除。
- 455例患者有随访内镜和病理结果(平均年龄67.1岁,女性42.2%,中位随访3.4年),包括HGD 269例、IMC 60例、T1 CRC 126例。
主要发现
- IMC患者完全内镜切除后手术比例为10.5%(6/57),HGD患者为0%(0/544),差异有统计学意义(P < .001)。
- HGD、IMC、T1 CRC三组同步进展性肿瘤比例分别为24.2%、26.7%、25.4%,无显著差异(P = .908)。
- 与HGD相比,IMC的异时性进展风险aHR为0.82(95%CI 0.43-1.59),T1 CRC的aHR为1.16(95%CI 0.66-2.05)。
- 无淋巴结阳性发现(0/363),IMC患者中未发生转移。
关键数值与推荐
- IMC完全内镜切除后手术比例10.5%(6/57) vs HGD 0%(0/544),P < .001。
- 同步进展性肿瘤比例:HGD 24.2% vs IMC 26.7% vs T1 CRC 25.4%,P = .908。
- 异时性进展风险:IMC vs HGD aHR 0.82(95%CI 0.43-1.59);T1 CRC vs HGD aHR 1.16(95%CI 0.66-2.05)。
- 淋巴结阳性:0/363。
临床怎么用
- 作者认为,除非患者特别关注IMC淋巴结转移的小风险,完全内镜切除应被视为IMC的 definitive 治疗,不应追加手术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: In the colorectum, intramucosal carcinoma (IMC), like high-grade dysplasia (HGD), should be resected endoscopically. We were interested to understand how real-world treatment of IMC cases compares to management of HGD and T1 colorectal cancer (CRC). METHODS: A multicenter cohort study was conducted. Through pathology databases, all patients diagnosed between 2010 and 2019 with HGD, IMC, or T1 CRC polyps at 3 hospitals in a regional Canadian center were identified. The primary outcome was the proportion of surgical management of IMC compared to HGD after complete endoscopic resection. Secondary outcomes were the proportion of synchronous advanced neoplasia (SAN) and the adjusted hazard ratios (aHRs) for metachronous advanced neoplasia (MAN) in the 3 groups among patients eligible for follow-up. RESULTS: We identified 753 patients with IMC or HGD on a first pathology diagnosis, including 601 after complete endoscopic resection. Patients with IMC were more likely to undergo surgery after complete endoscopic resection compared to patients with HGD (10.5% [6 of 57] vs 0% [0 of 544], P < .001). A total of 455 patients had follow-up endoscopy and pathology (mean age, 67.1 years; 42.2% female; median follow-up, 3.4 years): 269 with HGD, 60 with IMC, and 126 with T1 CRC. Proportions of SAN were 24.2%, 26.7%, and 25.4% (P = .908). Compared to HGD, patients with IMC and T1 CRC had similar MAN risks (aHR, 0.82 [95% CI, 0.43-1.59] and aHR, 1.16 [95% CI, 0.66-2.05], respectively). No lymph node findings were positive (0 of 363), and no metastasis occurred among patients with IMC. CONCLUSIONS: Patients diagnosed with colorectal IMC were more likely to undergo surgery after complete endoscopic resection than when HGD was diagnosed, although they were not at increased risk of SAN or MAN in this study, and the known risk of nodal metastasis with colorectal IMC is small (0%-2%). Unless a patient diagnosed with IMC is particularly concerned with this small risk, complete endoscopic resection should be considered the definitive treatment for IMC and should not be followed by surgery.
引用
- Medawar E, Djinbachian R, Rex DK, et al. Clinical management of patients with colorectal intramucosal carcinoma compared to high-grade dysplasia and T1 colorectal cancer. Gastrointest Endosc. 2024. PMID: 39557202. doi:10.1016/j.gie.2024.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。